GlassScriptPhysician profile
Rashmi Tomar
NPI 1902001837
$444.43
in general payments reported to CMS, 2019-2025
15 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2021: $14.08 · 2022: $99.18 · 2023: $69.84 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $190 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $190.34 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $114.04 | 2019-2022 | |
| Ucb, INC. | $75.16 | 2019-2025 | Bimzelx |
| Corcept Therapeutics | $28.45 | 2025 | Korlym |
| Tandem Diabetes Care, INC. | $26.95 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Almirall LLC | $24.26 | 2019 | |
| Neurocrine Biosciences, INC. | $24.04 | 2025 | |
| Sun Pharmaceutical Industries INC. | $23.52 | 2023 | Ilumya |
| Cequr Corporation | $19.50 | 2025 | Cequr Simplicity |
| Mylan Institutional INC. | $18.50 | 2023 | |
| Lnhc, INC | $18.37 | 2025 | Zelsuvmi |
| Lilly USA, LLC | $18.04 | 2019 | |
| Zealand Pharma US, INC. | $14.08 | 2021 | |
| Melinta Therapeutics, LLC | $13.70 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $13.49 | 2022 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rashmi Tomar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.